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164 C.-Y. Chen et al.Results: Of 3339 individuals,wedetected 34 cancers, yielding an overall cancer detection rate of
1.02%. There was a particularly high cancer detection rate of 6.2% (8/129) in the high-risk group
aged younger than 50 years with a positive family history of all types of cancers in first-degree
relatives. Adenocarcinomas accounted for 88% (30/34) of cancers and 99% of them were early-
stage (including carcinoma in situ and Stage I). The probability of cancers was significant higher
in nodules with interval growth (odds ratio 257.89, pZ 0.0002). There was no significant differ-
ence in the probability of cancers between ground glass opacity nodules and solid nodules (odds
ratio 1.16, pZ 0.72). Of all screen-detected cancers, 61.76% (21/34) were chest radiographi-
cally occult.
Conclusion: Low-doseCT is effective todetectearly lung cancers. Further establishmentof selec-
tion criteria for lung cancer screening, specifically for Asian individuals, is definitely warranted.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Lung cancer is the leading cause of cancer-related mor-
tality worldwide with> 1.3 million estimated deaths
annually.1 According to the Taiwan National Cancer Regis-
try, lung cancer is the fourth most common form of cancer
following breast, colon, and hepatobiliary cancer, and ac-
counts for the 12.09% of total number of newly reported
cancers. In Taiwan, lung cancer also ranks the highest in
terms of cancer-related mortality and accounts for 19.67%
of all cancers in 2012.2 Despite recent advances in surgical,
radiotherapeutic, and chemotherapeutic approaches, the
long-term survival of patients with lung cancer remains
poor. The 5-year survival rate for lung cancer is only 15.9%
in Taiwan, with a median survival of 13.2 months.3 A key
point is that most patients have advanced-stage lung can-
cer at initial diagnosis, while the opportunity for potentially
curative interventions is lost.
In a bid to reduce the mortality of lung cancer, ran-
domized trials have been performed over many years with
various methods including the use of chest radiography with
or without cytological analysis of sputum specimens. How-
ever, the analysis demonstrated that there was no differ-
ence in mortality between the screened and the control
groups4e6 and therefore no medical organizations recom-
mend screening with chest radiography. Recently, lung
cancer screening using low-dose computed tomography
(CT) has been carried out in many countries and reported to
be effective in detecting lung cancer at a smaller size and
earlier stage. In 2011, the National Lung Screening Trial
(NLST), the world’s largest randomized CT screening trial,
demonstrated a 20% reduction in lung cancer-specific
mortality with low-dose CT screening compared to
screening by chest radiography in high-risk current and
former smokers.7 Following the publication of the NLST
results and subsequent analysis of the NLST cohort, several
organizations, including National Comprehensive Cancer
Network, American College of Chest Physicians (ACCP), and
American Society of Clinical Oncology (ASCO) issued formal
guidelines for lung cancer screening respectively with
similar recommendations on the primary population for
screening.8,9 Furthermore, other ongoing European ran-
domized lung cancer screening trials will validate the NLST
results and also provide information on the optimal lengthof the screen interval and the mortality benefit compared
to control arm in which individuals receive no screening.10
However, before implementation of low-dose CT for lung
cancer screening as a national health policy,11 there are
two major questions that need to be answered directly.
First, will other populations at risk of lung cancer rather
than tobacco smoking benefit from CT screening? Second,
can the NLST results be replicated in the community
setting?
We report here the findings of lung cancer screening by a
tertiary hospital, including the overall detection rate of
lung cancers using low-dose CT screening in a comprehen-
sive self-referral program outside a controlled research
setting and to compare differences in the pathologic and
imaging findings of detected lung cancers in asymptomatic
individuals in Taiwan.Methods
During the 1-year period from January 1, 2012 to December
31, 2012, we conducted a single-center population-based
screening program for lung cancer in the setting of annual
medical examinations. The service was provided to in-
habitants in Taichung City and employees of the China
Medical University Hospital, Taichung, Taiwan on a self-
referral basis. Participants were asymptomatic adults aged
18 years or older and had no prior history of any cancer. A
history of cigarette smoking was not necessary for entrance
into the study. For each individual visiting for annual
medical examination, relevant clinical notes, previous op-
erations, family history of all types of cancer in first-degree
relatives, and other risk factors for lung cancer including
cigarette smoking were documented and a physical exam-
ination was performed by a dedicated family physician. All
participants were enrolled into the study only after written
informed consent.
Screening CT and chest radiography
Low-dose CT and chest radiography were offered to all in-
dividuals who joined lung cancer screening. All CT scans
were performed on thin-slice (0.625 mm) scanners from
different manufacturers (General Electric Medical Systems,
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Japan) with variable numbers of detectors (16e320), from
lung apex to base without contrast enhancement. The CT
scanners included GE LightSpeed 16 Slice CT scanner, GE
BrightSpeed 16 Slice CT scanner, GE LightSpeed VCT 64 slice
CT scanner, and Toshiba Aquilion One 320 slice CT scanner.
All scans were obtained using a low-dose regimen, with the
machine set at 120 kVp, 9 (15 mA/0.6 s) or 21 (35 mA/0.6 s)
mAs, 1.5:1 pitch ratio, and 0.6 seconds rotation time. The
effective radiation dose ranged from 0.3 mSv to 0.8 mSv. All
chest radiographs were acquired using Toshiba KXO-50R
Radiographic Systems.
All CT images were interpreted on a dedicated work-
station, using a commercially available dedicated software
tool (AW 4.6, GE Healthcare) by one of four thoracic radi-
ologists with 2 years, 4 years, 11 years, and 18 years of
chest CT imaging experience, respectively. Axial and cor-
onal maximum intensity projection images with slab
thicknesses of 5 mm were made on workstation to detect
the lung nodules and size measurement step by step. The
CT images were interpreted on Totoku grayscale diagnostic
monitors (MS33i2, Totoku Electric Co., Tokyo, Japan) with
resolutions of 3 megapixels. The images were displayed
with the fixed lung window setting (window width, 6000 HU;
window level, 600 HU) and mediastinal window (window
width, 400 HU; window level, 35 HU).
We evaluated the attenuation (classified into: solid,
pure ground-glass, partial ground-glass opacity, or calcified
nodules) and size of nodules (according to the longest
perpendicular diameter: < 4 mm or > 4 mm). The solid
nodules are defined as nodule densities completely equal or
higher than pulmonary vessel. Pure ground-glass opacity
nodules are the nodules of increased pulmonary attenua-
tion with preservation of the bronchial and pulmonary
vascular margins with no completely obscured parenchyma.
Partial ground-glass opacity nodules are nodules that have
both ground-glass and solid components. Calcified nodules
are lung nodules with any patterns of calcifications. Base-
line CT evaluations were defined as positive if any non-
calcified nodule 4 mm in diameter was identified.
Baseline chest radiography evaluations were defined as
positive if any visible nodules or other clinical significant
abnormalities were identified. Other clinical significant
abnormalities include atelectasis, pleural thickening or
effusion, hilar or mediastinal lesion, chest wall abnormal-
ity, alveolar or interstitial opacities, and fibrosis. All in-
dividuals with positive findings detected on baseline CT
scans or chest radiographs were automatically referred to
appropriate thoracic surgeons or pulmonologists for expert
evaluations.
There were weekly multidisciplinary lung cancer meet-
ings where thoracic radiologists, surgeons, and pulmonol-
ogists from the China Medical University Hospital jointly
reviewed and discussed the management plan of individuals
with abnormal CT scans or chest radiographs.
Management recommendations, including follow-up low-
dose CT scans, positron emission tomography-CT, immedi-
ate transthoracic needle biopsy, video-assisted thoraco-
scopic surgery, or bronchoscopic biopsy, were made by
each attending physicians. The most appropriate approach
was selected to suit their practice routine based on anonscientifically validated, internally developed manage-
ment algorithm (Figure 1), clinician experience, and de-
cisions of individuals with screening detected nodules. All
individuals with screening detected lung cancers were
traced and the corresponding low-dose CT scans, chest ra-
diographs, clinical notes, and pathology reports were
reviewed.Results
During the 1-year period from January 1, 2012 to December
31, 2012, 3339 asymptomatic individuals attended our
screening program for lung cancer and a total of 3576 low-
dose CT scans were performed. There were 1746 men and
1593 women, averaging age 48 years (range, 19e86 years;
standard deviation 11.5 years). A total of 22.1% of the pa-
tients were aged 30e39 years; 28.7% were aged
40e49 years; 29.3% were aged 50e59 years, and 16.2% were
aged 60 years or above. There were 893 former smokers,
845 current smokers, and 1661 never-smokers. There were
129 patients younger than 50 years with a positive family
history of cancer who attended for lung cancer screening;
they constituted 3.9% of the total attendance (Table 1).
Following the definitions described above, 1279 in-
dividuals (38.3%) had positive baseline CT findings. During
the study period, 237 individuals underwent follow-up low-
dose CT scans, which were performed 3 months or 6 months
after the initial examinations. As a result of abnormal
findings described at the baseline and follow-up low-dose
CT scans, 41 individuals underwent immediate or delayed
diagnostic evaluation with surgical removal of the nodule,
which was followed by curative pulmonary resection if the
presence of malignancy was documented at frozen resec-
tion. Figure 2 indicates the follow-up and outcomes of in-
dividuals examined.
Of 3339 individuals undergoing low-dose CT for lung
cancer screening during the study, we detected 34 cancers,
which gave an overall cancer detection rate of 1.02% (Table
2). The age range of the patients detected with cancers was
26e72 years with a median of 47 years. Of the 34 screening-
detected cancers, 11 (32%) cancers were found in never-
smokers, seven (20%) cancers were found among former
smokers, and 16 (47%) cancers were found in current
smokers. Our cancer detection rate was 1.35% (10 of 739) in
the age-group 30e39 years, 0.94% (9 of 958) in the age-
group 40e49 years, and 0.92% (14 of 1518) in the age-
group 50 years or above. In our study, there was a partic-
ularly high cancer detection rate of 6.2% (8 of 129) in the
high-risk group aged younger than 50 years with a positive
family history of first-degree relatives having cancers.
Of the 34 screening-detected cancers on CT scans,
cancers presented as pure ground-glass opacity nodules in
22 patients, partial ground-glass opacity nodules in two
patients, and solid nodules in 10 patients. In order to
reduce bias, the difference in the probability of cancers
between ground-glass opacity and solid nodules, was
calculated only on the basis of individuals who had received
regular follow-up or management included (Figure 2). The
probability of cancers was higher in ground-glass opacity
nodules (24 of 119, 20.17%) than in solid nodules (10 of 56,
Table 1 Characteristics of the study population.
Factor Description n (%)
Sex Male 1746 (52.3)
Female 1593 (47.7)
Age group (y) 19e29 124 (3.7)
30e39 739 (22.1)
40e49 958 (28.7)
50e59 978 (29.3)
60e69 414 (12.4)
70e79 115 (3.4)
80e89 11 (0.3)
Cigarette history Never-smoker 1601 (47.9)
Former smoker 893 (26.7)
Current smoker 845 (25.3)
Family history of cancers Present 129 (3.9)
Absent 3210 (96.1)
Pulmonary 
nodule(s)
Calcified nodule
OR
< 4 mm nodule
Surveillance
Ground-glass
Opacitya
High risk
Biopsy/Surgery
Low risk
Follow-up CT 
at 3 months
Increased size
Biopsy/Surgery
Stable
Surveillance
Solid nodule
> 8 mm nodule
Biopsy
<8 mm nodule
High risk
Biopsy/Surgery
Low risk
Follow-up CT
at 6 months
Increased size
Biopsy/Surgery
Stable
Surveillance
Figure 1 Management algorithm for pulmonary nodules detected by low-dose computed tomography (CT) scans. Recommen-
dation is based on the attenuation and size of nodules. Risk stratification is determined by age, cigarette history, and family history
of cancers. The high risk group includes any of the following criteria: beyond age 50 years, history of cigarette smoking, or presence
of family history of cancer. The low risk group is defined as none of above. aNodules with ground-glass opacity include nodules with
pure and partial ground-glass opacity.
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1.16, p Z 0.72).
All the cancers were detected from the prevalent (1st)
round of screening, while the majority of them (27 of 34,
79.41%) were diagnosed after follow-up low-dose CT scans.
Of these, the probability of cancers was significantly higher
in nodules with interval growth (13 of 13, 100%) than in
nodules without interval change (14 of 152, 9.21%; odds
ratio 257.89, p< 0.001). So far, we have not encountered
any cases of interval cancers (i.e., lung cancers thatpresented and were diagnosed during the follow-up period
and not detected by our screening program) during the
study period.
Pathology reports of these 34 screening-detected cancer
patients were available for review. Of the 34 patients with
cancers, 30 (88%) had adenocarcinomas, three (8%) had
invasive thymoma, and one (3%) had a germinoma. Of the
30 patients with adenocarcinoma, adenocarcinoma in situ
was seen in 12 (40%), Stage IA (14 T1a and 2 T1b) in 16
(53.3%) patients, Stage IB in one (3.3%) patient, and Stage
IIIA in one (3.3%) patient. All of them underwent potentially
curable pulmonary resection via video-assisted thoraco-
scopy and four patients received adjuvant chemotherapy.
During the study period, there have been no major com-
plications documented following an invasive procedure for
a positive CT finding thus far.
Abnormal findings including visible nodules and other
clinical significant abnormalities were detected by chest
radiographs in 477 (14.03%) of these asymptomatic in-
dividuals. Of 477 individuals with abnormal findings
detected by chest radiographs, 21 (4.4%) had visible
nodules and 456 (95.6%) had other clinical significant ab-
normalities. Thirteen of 477 individuals with abnormal
findings detected by chest radiographs had cancers, which
gave a cancer detection rate of 2.73%. However, 21 of
2862 individuals with normal chest radiographs had can-
cers and thus 61.76% (21 of 34) of all screening-detected
cancers were chest radiographically occult. Table 3 in-
dicates the screening performance during the study
period.
Total screened
n = 3339
NegaƟve 
baseline
n = 2060
PosiƟve 
baseline
n = 1279
Ground-glass 
Opacitya
n = 367
Surveillance
n = 248
Follow-up CT
n = 110
Increased size
Biopsy/Surgery
n = 6 
malignancy
n = 6
Stable
Biopsy/Surgery
n = 17
Malignancy
n = 12 
Stable
Surveillance
n = 87
Biopsy/Surgery
n = 9
Malignancy
n = 6
Solid nodule
n = 912
Surveillance
n = 856
Follow-up CT
n = 55 
Increased size
Biopsy/Surgery
n = 7
Malignancy
n = 7
Stable
Biopsy/Surgery
n = 4
Malignancy
n = 2
Stable
Surveillance
n = 44
Biopsy/Surgery
n = 1
Malignancy
n = 1
Figure 2 Follow-up and outcome of baseline low-dose computed tomography (CT) scans. aNodules with ground-glass opacity
include nodules with pure and partial ground-glass opacity.
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Recently, the analysis from NLST reported favorable effi-
ciency and cost-effectiveness results for lung cancer
screening with low-dose CT.12 Meanwhile, more and more
evidence from other ongoing high-quality randomized
controlled trials13,14 will demonstrate the benefits of low-
dose CT, based on reports of significant reductions in mor-
tality to validate the NLST results. However, most of these
studies were conducted for individuals with a history of
cigarette smoking in North America and Europe.15,16
Furthermore, the epidemiological, demographic, clinical,
and histological features of lung cancer, and the cost
associated with lung cancer screening and health care
setting in these countries are considered to be different
from Taiwan.17,18 These considerations prompted us to
evaluate the performance of lung cancer screening with
low-dose CT in the setting of annual medical examinations
in Taiwan.
In our study, the overall cancer detection rate by low-
dose CT (1.02%) was lower than previously reported (3.3%)
in the Early Lung Cancer Action Project study.19 We offer
two possible explanations. First, all the participants in our
study attended for screening on a voluntary, self-referral
basis. The recruitment criteria did not have any restric-
tion on the population potentially at high risk of lung cancer
because of age and a history of cigarette smoking. As a
result, 1601 (47.95%) never-smokers and 1699 (49.98%) in-
dividuals aged younger than 50 years of our study popula-
tion would be considered as low-risk group and routine lung
cancer screening would not be recommended according to
the National Comprehensive Cancer Network guidelines.
Consistent with this explanation, the overall cancer
detection rate was also lower (0.36e1.1%) in the Japa-
nese20 and Korean studies.21 Second, in the setting withonly passive follow-up, there was a large recognition gap
between individuals’ preference, compliance, and man-
agement recommendations. Therefore, the cancer detec-
tion rate might be underestimated to an unknown degree
since not all individuals with positive CT findings and
concomitant high-risk features, including nodules with
ground-glass opacity and interval growth, would receive
diagnostic evaluation eventually.
Our first important finding is that the cancer detection
rate in the group aged younger than 50 years with family
history of all types of cancers in first-degree relatives,
regardless of smoking status, was particularly high (6.2%).
In Asia, patients with lung cancer tended to have a younger
age of onset and about 30% of them were never-smokers.22
In the meanwhile, besides tobacco smoking,23 it has also
been described that family history of cancers was associ-
ated with risk of lung cancer and risk appeared to be
greater in those with relatives with early age at diagnosis or
multiple affected family members.24 Despite the contro-
versial relationship between ethnicity, young age, family
history, and never-smokers, other different environmental
exposure and genetic susceptibility might play important
roles in the connection of these four conditions and the
development of lung cancer.25 The intention of our study is
to highlight that a different selection criteria for lung
cancer screening in Asian has the potential to be a worth-
while health care strategy.
The second important finding is that concomitant fea-
tures of CT scan, including nodules with and interval
growth, indicated a significant positive association with
lung cancer. The odds ratio for nodules interval growth
related to lung cancer was 257.89. Previous studies had
similar results, strengthening the conclusion that visual
characteristics and descriptors were helpful in manage-
ment of nodules detected on CT scans under the current
Table 2 Characteristics of detected lung cancers by low-dose CT screening.a
No. Sex Age (y) Types of attenuation Histology TNM Stage Treatment
1 Female 50 12 mm GGO, RUL Adenocarcinoma T1aN0M0 IA Lobectomy
2 Male 37 6.5 mm GGO, RUL Adenocarcinoma in situ TisN0M0 0 Lobectomy
3 Female 37 10 mm GGO, LUL Adenocarcinoma T1aN0M0 IA Lobectomy
4 Male 50 8.5 mm GGO, LUL Adenocarcinoma T1aN0M0 IA Lobectomy
5 Female 44 9 mm GGO, LUL Adenocarcinoma in situ TisN0M0 0 Wedge resection
6 Female 46 17 mm solid, RML Adenocarcinoma T1aN0M0 IA Lobectomy
7 Female 54 7 mm GGO, RUL Adenocarcinoma T1aN0M0 IA Wedge resection
8 Male 35 7.5 mm GGO, RLL Adenocarcinoma T1aN0M0 IA Wedge resection
9 Female 47 10 mm GGO, LUL Adenocarcinoma T1aN0M0 IA Lobectomy
10 Male 64 19 mm GGO, RLL Adenocarcinoma T1aN0M0 IA Lobectomy
11 Female 48 7.5 mm GGO, LLL Adenocarcinoma in situ TisN0M0 0 Wedge resection
12 Female 51 6.5 mm GGO, RML Adenocarcinoma T1aN0M0 IA Wedge resection
13 Male 52 18 mm solid, RML Adenocarcinoma T1bN0M0 IA Lobectomy
14 Female 50 8.2 mm GGO, LLL Adenocarcinoma T4N0M0 IIIA Lobectomy
15 Male 72 10 mm solid, LLL Adenocarcinoma T1aN0M0 IA Lobectomy
16 Female 34 8 mm GGO, LLL Adenocarcinoma in situ TisN0M0 0 Wedge resection
17 Female 35 8 mm GGO, RUL Adenocarcinoma in situ TisN0M0 0 Wedge resection
18 Male 60 8 mm GGO, RUL Adenocarcinoma in situ TisN0M0 0 Wedge resection
19 Female 56 23 mm solid, LLL Adenocarcinoma T1bN0M0 IA Lobectomy
20 Female 65 12 mm solid, LLL Adenocarcinoma T1aN0M0 IA Lobectomy
21 Male 33 7 mm GGO, LLL Adenocarcinoma in situ TisN0M0 0 Wedge resection
22 Female 42 7.5 mm GGO, RLL Adenocarcinoma in situ TisN0M0 0 Wedge resection
23 Male 39 7 mm GGO, LUL Adenocarcinoma in situ TisN0M0 0 Wedge resection
24 Male 72 9 mm GGO, LUL Adenocarcinoma T1aN0M0 IA Wedge resection
25 Female 47 10 mm GGO, LUL Adenocarcinoma in situ TisN0M0 0 Wedge resection
26 Female 43 7 mm GGO, LUL Adenocarcinoma in situ TisN0M0 0 Wedge resection
27 Female 62 7 mm GGO, RLL Adenocarcinoma T2aN0M0 IB Lobectomy
28 Female 44 18 mm solid, RLL Adenocarcinoma T1aN0M0 IA Lobectomy
29 Female 37 9 mm GGO, RML Adenocarcinoma in situ TisN0M0 0 Wedge resection
30 Male 61 9 mm GGO, LLL Adenocarcinoma T1aN0M0 IA Wedge resection
GGO Z ground-glass opacity; LLL Z left lower lobe; LUL Z left upper lobe; RLL Z right lower lobe; RML Z right middle lobe;
RUL Z right upper lobe; Tis Z carcinoma in situ.
a Of the 30 patients with screening-detected lung cancers, 14 underwent thoracoscopic lobectomy and 16 underwent thoracoscopic
wedge resection. All of them underwent hilar and mediastinal lymph nodes dissection at the same time with pulmonary resection.
Nodules with ground-glass opacity include nodules with pure and partial ground-glass opacity.
Table 3 Performance characteristics of screening methods.
True
positive
False
negative
False
positive
True
negative
Sensitivity
(%)
Specificity
(%)
Positive predictive
value (%)
Negative predictive
value (%)
Low-dose computed
tomography
34 0 1245 2060 100 62.3 2.7 100
Chest radiography 13 21 464 2841 38.2 85.9 2.7 99.3
168 C.-Y. Chen et al.practice.26,27 Further technologies used to aid decision
making, including quantitative and multimodality
approach, will become widespread in the near future.
Regarding the management algorithm of our study,
80.49% (34 of 41) of individuals who received diagnostic
evaluation, were diagnosed as cancer eventually. As in most
previous studies,28 adenocarcinomas were oversampled
with approximately two- to three-fold, accounting for 88%
(30 of 34) of cancers in our study population. Among those
with adenocarcinoma, adenocarcinoma in situ was seen in
12 (40%), Stage IA (14 T1a and 2 T1b) in 16 (53.3%) patients,and Stage IB in 1 (3.3%) patients. Compared with previous
Western and Japanese studies,29 the percentage of early-
stage lung (96.6%, including carcinoma in situ and Stage I)
was higher and almost all adenocarcinomas in our study
were potentially curable after pulmonary resection.
Despite particularly early diagnosis of lung cancer, our
management algorithm still provided a high enough positive
predictive value for any positive finding that led to diag-
nostic evaluation.30
Although annual screening with chest radiograph did not
reduce lung cancer mortality by the Prostate, Lung,
Low dose CT for lung cancer 169Colorectal, and Ovarian cancer screening trial,31 with
respect to the existing results of the NLST, there are still
many debates over implementation of low-dose CT for lung
cancer screening as a national health policy. The potential
shortcomings include false-positive results, financial costs,
radiation exposure, and unnecessary numerous diagnostic
workups and complications from the procedures.32 By
contrast, chest radiograph could be another screening tool
of choice for early detection of lung cancer without the
additional shortcomings of low-dose CT. Furthermore, a
recent population-based cohort study demonstrated an 18%
reduction of lung cancer mortality with chest radiograph
screening.33 However, our study showed that 61.76% of all
screen-detected cancers were chest radiographically
occult, suggesting that chest radiograph alone may not be
sufficient to exclude malignancy. Its exact application re-
mains to be determined in the future.
Notwithstanding the comparative results, there were
several limitations associated our screening program. First,
self-referral setting with self-paid medical expenses of low-
dose CT invariably attracted individuals with more health
consciousness, suggesting selection bias in our study. Sec-
ond, not all individuals with positive baseline CT findings
received regular follow-up and management as recom-
mendation. They had free choices to seek second opinions
or diagnostic evaluations in other hospitals, partly because
of convenience in accessing medical care in Taiwan.
Therefore, there might be some patients having lung can-
cers that were detected by our baseline CT scans but not
included in the present study. The third limitation was that
our study period was short (18 months at most) compared
with NLST and other ongoing European randomized lung
cancer screening trials (3 years at least), and, thus, the
overall cancer detection must be underestimated. It
seemed difficult to correct the true cancer detection rate
on the current retrospective basis and the subsequent in-
fluence on the importance of family history of cancer and
interval growth was unpredictable.
We defined family history of cancer as the presence of
first-degree relatives with all types of cancer in our study.
However, several potential limitations about family history
of cancer in our study should be also considered. First,
family history of cancer was assessed using self-
administered questionnaires but not the cancer registry
database. The accuracy of self-reported data may not al-
ways be satisfactory. Second, detailed information on age
at diagnosis and cell type of cancer was not collected
completely. In our study, we can only highlight the high
detection rate in young and middle-aged individuals with a
family history of cancer. Further investigation on the as-
sociation of lung cancer risk with family history of different
types of cancer is definitely warranted to improve clinical
practice.
In conclusion, our study qualified the efficiency of low-
dose CT to detect early lung cancers. Moreover, the result
demonstrated that a particularly high detection rate in
young and middle-aged individuals with a family history of
cancers. Therefore, further establishment of selection
criteria specifically for Asian individuals and lung cancer
screening protocols with systems integration by govern-
ment are definitely warranted to improve cost-
effectiveness and outcomes for lung cancer patients.References
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